Matches in Wikidata for { <http://www.wikidata.org/entity/Q94668768> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q94668768 description "article scientifique publié en 2020" @default.
- Q94668768 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q94668768 description "scientific article published on 13 May 2020" @default.
- Q94668768 description "wetenschappelijk artikel" @default.
- Q94668768 description "наукова стаття, опублікована 13 травня 2020" @default.
- Q94668768 name "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 name "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 type Item @default.
- Q94668768 label "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 label "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 prefLabel "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 prefLabel "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II an" @default.
- Q94668768 P1433 Q94668768-D311717A-1C86-4D90-B0F1-5E439D216043 @default.
- Q94668768 P1476 Q94668768-836D341C-4FB6-4109-9839-962E980C20CF @default.
- Q94668768 P2093 Q94668768-053D6D43-AFBF-4577-B377-BDE869D7FA5C @default.
- Q94668768 P2093 Q94668768-58C7B640-0ACE-447E-9E46-08A91C26F8CE @default.
- Q94668768 P2093 Q94668768-74E10744-C9EA-462A-B43B-3130A1793AAE @default.
- Q94668768 P2093 Q94668768-91613F11-E1A5-419E-9394-87ADEB82F48B @default.
- Q94668768 P2093 Q94668768-9F4A5212-0108-40B0-8DF4-5D04C3195DDB @default.
- Q94668768 P2093 Q94668768-B0E438EE-30C8-47E7-8268-65314C0434D7 @default.
- Q94668768 P2093 Q94668768-D4E91DAC-0B22-4F4D-8622-2EA08812D85A @default.
- Q94668768 P2093 Q94668768-DB7079C1-6A45-4E3A-BA28-FEAD235C0A56 @default.
- Q94668768 P2093 Q94668768-E084B892-5B09-402A-AA9F-5C3E2725F0DE @default.
- Q94668768 P304 Q94668768-BFBAA243-FD67-4D43-97CE-C46D479DD7AC @default.
- Q94668768 P31 Q94668768-94B4D1AA-D6CE-4AE7-AB4D-2F72F681527D @default.
- Q94668768 P356 Q94668768-0E852673-BEA0-4BC7-9F90-5DA057EBCE63 @default.
- Q94668768 P433 Q94668768-9AA98C99-C9A7-41A1-B373-7B8CB83CEACF @default.
- Q94668768 P478 Q94668768-4C4CFB16-48C5-46F6-A1B9-713E83972301 @default.
- Q94668768 P50 Q94668768-6603B45A-2B35-4151-B8CF-2EE504D2D6A6 @default.
- Q94668768 P577 Q94668768-5E953172-FA40-40F7-84DB-61A10804AC80 @default.
- Q94668768 P698 Q94668768-5133747A-E811-4681-A473-D572C80D4058 @default.
- Q94668768 P932 Q94668768-900CAC0F-772C-47DE-9545-8C6FE6B71A47 @default.
- Q94668768 P356 S12885-020-06933-Y @default.
- Q94668768 P698 32404154 @default.
- Q94668768 P1433 Q326300 @default.
- Q94668768 P1476 "Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials" @default.
- Q94668768 P2093 "Angela Toss" @default.
- Q94668768 P2093 "Chrystel Isca" @default.
- Q94668768 P2093 "Elena Barbieri" @default.
- Q94668768 P2093 "Federico Piacentini" @default.
- Q94668768 P2093 "Isabella Sperduti" @default.
- Q94668768 P2093 "Laura Cortesi" @default.
- Q94668768 P2093 "Luca Moscetti" @default.
- Q94668768 P2093 "Massimo Dominici" @default.
- Q94668768 P2093 "Monica Barbolini" @default.
- Q94668768 P304 "418" @default.
- Q94668768 P31 Q13442814 @default.
- Q94668768 P356 "10.1186/S12885-020-06933-Y" @default.
- Q94668768 P433 "1" @default.
- Q94668768 P478 "20" @default.
- Q94668768 P50 Q60683018 @default.
- Q94668768 P577 "2020-05-13T00:00:00Z" @default.
- Q94668768 P698 "32404154" @default.
- Q94668768 P932 "7222291" @default.